-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
MaxCyte (NASDAQ:MXCT) Versus Absci (NASDAQ:ABSI) Head-To-Head Analysis
MaxCyte (NASDAQ:MXCT) Versus Absci (NASDAQ:ABSI) Head-To-Head Analysis
MaxCyte (NASDAQ:MXCT – Get Rating) and Absci (NASDAQ:ABSI – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability and earnings.
Analyst Recommendations
This is a breakdown of recent ratings for MaxCyte and Absci, as provided by MarketBeat.
Get MaxCyte alerts:Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
MaxCyte | 0 | 0 | 1 | 0 | 3.00 |
Absci | 2 | 0 | 5 | 0 | 2.43 |
MaxCyte presently has a consensus price target of $11.00, suggesting a potential upside of 85.50%. Absci has a consensus price target of $14.00, suggesting a potential upside of 250.00%. Given Absci's higher probable upside, analysts clearly believe Absci is more favorable than MaxCyte.
Volatility and Risk
MaxCyte has a beta of 1.17, meaning that its stock price is 17% more volatile than the S&P 500. Comparatively, Absci has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500.Institutional & Insider Ownership
66.4% of MaxCyte shares are owned by institutional investors. Comparatively, 45.4% of Absci shares are owned by institutional investors. 5.1% of MaxCyte shares are owned by insiders. Comparatively, 19.4% of Absci shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares MaxCyte and Absci's net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
MaxCyte | -47.92% | -7.60% | -6.96% |
Absci | -2,223.07% | -29.31% | -25.26% |
Earnings and Valuation
This table compares MaxCyte and Absci's top-line revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
MaxCyte | $33.89 million | 17.82 | -$19.08 million | ($0.20) | -29.65 |
Absci | $4.78 million | 77.69 | -$100.96 million | ($1.26) | -3.17 |
MaxCyte has higher revenue and earnings than Absci. MaxCyte is trading at a lower price-to-earnings ratio than Absci, indicating that it is currently the more affordable of the two stocks.
Summary
MaxCyte beats Absci on 9 of the 14 factors compared between the two stocks.
About MaxCyte
(Get Rating)
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.
About Absci
(Get Rating)
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.
MaxCyte (NASDAQ:MXCT – Get Rating) and Absci (NASDAQ:ABSI – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability and earnings.
纳斯达克(MXCT-GET Rating)和ABSCI(纳斯达克:ABSI-GET Rating)都是小盘医疗公司,但哪种投资更好?我们将根据这两家公司的股息实力、风险、分析师建议、估值、机构所有权、盈利能力和收益进行比较。
Analyst Recommendations
分析师建议
This is a breakdown of recent ratings for MaxCyte and Absci, as provided by MarketBeat.
这是MarketBeat提供的MaxCyte和Absci最近的评级细目。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
MaxCyte | 0 | 0 | 1 | 0 | 3.00 |
Absci | 2 | 0 | 5 | 0 | 2.43 |
销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
Maxcell | 0 | 0 | 1 | 0 | 3.00 |
ABSCI | 2 | 0 | 5 | 0 | 2.43 |
MaxCyte presently has a consensus price target of $11.00, suggesting a potential upside of 85.50%. Absci has a consensus price target of $14.00, suggesting a potential upside of 250.00%. Given Absci's higher probable upside, analysts clearly believe Absci is more favorable than MaxCyte.
Maxcell目前的共识目标价为11.00美元,这意味着潜在的上行空间为85.50%。Absci的普遍目标价为14.00美元,暗示潜在上行250.00%。鉴于Absci更有可能上行,分析师显然认为Absci比MaxCyte更有利。
Volatility and Risk
波动性和风险
Institutional & Insider Ownership
机构与内部人持股
66.4% of MaxCyte shares are owned by institutional investors. Comparatively, 45.4% of Absci shares are owned by institutional investors. 5.1% of MaxCyte shares are owned by insiders. Comparatively, 19.4% of Absci shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
MaxCyte 66.4%的股份由机构投资者持有。相比之下,ABSCI 45.4%的股份由机构投资者持有。MaxCyte 5.1%的股份由内部人士持有。相比之下,ABSCI 19.4%的股份由内部人士持有。强大的机构持股表明,大型基金管理公司、捐赠基金和对冲基金相信,一只股票的长期表现将好于大盘。
Profitability
盈利能力
This table compares MaxCyte and Absci's net margins, return on equity and return on assets.
下表比较了MaxCyte和Absci的净利润率、股本回报率和资产回报率。
Net Margins | Return on Equity | Return on Assets | |
MaxCyte | -47.92% | -7.60% | -6.96% |
Absci | -2,223.07% | -29.31% | -25.26% |
净利润率 | 股本回报率 | 资产回报率 | |
Maxcell | -47.92% | -7.60% | -6.96% |
ABSCI | -2,223.07% | -29.31% | -25.26% |
Earnings and Valuation
收益和估值
This table compares MaxCyte and Absci's top-line revenue, earnings per share and valuation.
该表格比较了MaxCyte和Absci的营收、每股收益和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
MaxCyte | $33.89 million | 17.82 | -$19.08 million | ($0.20) | -29.65 |
Absci | $4.78 million | 77.69 | -$100.96 million | ($1.26) | -3.17 |
总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
Maxcell | 3389万美元 | 17.82 | -1908万美元 | ($0.20) | -29.65 |
ABSCI | 478万美元 | 77.69 | -1.096亿元 | ($1.26) | -3.17 |
MaxCyte has higher revenue and earnings than Absci. MaxCyte is trading at a lower price-to-earnings ratio than Absci, indicating that it is currently the more affordable of the two stocks.
Maxcell的收入和收益比Absci更高。Maxcell的市盈率低于Absci,表明它目前是两只股票中更负担得起的一只。
Summary
摘要
MaxCyte beats Absci on 9 of the 14 factors compared between the two stocks.
Maxcell在两只股票之间的14个因素中有9个超过了Absci。
About MaxCyte
关于MaxCyte
(Get Rating)
(获取评级)
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.
Maxcell,Inc.是一家全球生命科学公司,致力于下一代细胞疗法的发现、开发和商业化。其产品包括:Expert ATx,一种用于中小规模转基因的静态电穿孔仪器;Expert STx,一种用于蛋白质生产和药物开发的流动电穿孔设备,以及用于基于细胞分析的治疗靶点的表达;Expert GTx,一种用于治疗应用中大规模转基因的流动电穿孔设备;以及Expert VLx,用于超大规模细胞工程。该公司还提供用于处理和电穿孔电池的一次性处理组件(PAS);以及支持PAS的配件,如电穿孔缓冲液和软件协议。该公司成立于1998年,总部设在马里兰州的罗克维尔。
About Absci
关于ABSCI
(Get Rating)
(获取评级)
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.
ABSCI公司是一家药物和靶点发现公司,利用集成的药物创造平台为美国的合作伙伴提供生物药物候选和生产细胞系。其集成的药物创造平台通过将药物发现和细胞系开发过程统一到一个过程中来实现生物制剂的创造。Absci Corporation成立于2011年,总部位于华盛顿州温哥华。
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.
接收MaxCyte日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对MaxCyte和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧